The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tremelimumab and durvalumab (MEDI4736) combination for first and second-line treatment of mesothelioma patients: The NIBIT-MESO-1 study.
 
Luana Calabrò
Research Funding - AstraZeneca/MedImmune (Inst)
 
Aldo Morra
No Relationships to Disclose
 
Diana Giannarelli
No Relationships to Disclose
 
Diego Annesi
No Relationships to Disclose
 
Erica Bertocci
No Relationships to Disclose
 
Riccardo Danielli
No Relationships to Disclose
 
Maresa Altomonte
No Relationships to Disclose
 
Anna Maria Di Giacomo
Research Funding - Astex Pharmaceuticals; Bristol-Myers Squibb
 
Michele Maio
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Roche/Genentech
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb